Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…Abstract Number: 2596 • ACR Convergence 2023
Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Background/Purpose: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) with the current best evidence for the treatment of systemic…Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…Abstract Number: 0651 • ACR Convergence 2023
Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry
Background/Purpose: The aim of this study is to describe the nailfold video-capillaroscopy (NVC) findings in patients with interstitial lung disease associated to connective tissue diseases…Abstract Number: 0950 • ACR Convergence 2023
KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as…Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…Abstract Number: 1734 • ACR Convergence 2023
Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA), such as interstitial lung disease (RA-ILD), are a major contributor to morbidity and mortality. The mechanism of pulmonary…Abstract Number: 2172 • ACR Convergence 2023
Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown…Abstract Number: 0307 • ACR Convergence 2023
Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is frequently complicated by rapidly progressive interstitial lung disease (ILD) and is life-threatening especially in the…Abstract Number: 0652 • ACR Convergence 2023
Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
Background/Purpose: Systemic sclerosis (SSc) is a multisystem fibrosing autoimmune disease with a high mortality rate. Ethnicity can influence prevalence and disease characteristics in SSc. Less…Abstract Number: 1034 • ACR Convergence 2023
The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts
Background/Purpose: For patients with autoimmune interstitial lung disease (ILD), the clinician's interpretation of the extent of ground glass relative to fibrosis on imaging often influences…Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…Abstract Number: 1764 • ACR Convergence 2023
Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) causes significant complications and mortality in patients with rheumatoid arthritis (RA). We have previously shown that patients with RA-ILD had…Abstract Number: 2173 • ACR Convergence 2023
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 39
- Next Page »